Edition:
United Kingdom

Orexigen announces favorable decision from U.S. court in patent litigation, confirming exclusivity for Contrave through 2030


Friday, 13 Oct 2017 

Oct 13 (Reuters) - Orexigen Therapeutics Inc ::Orexigen announces favorable decision from U.S. District Court in patent litigation, confirming exclusivity for Contrave through 2030.Orexigen therapeutics - U.S. Court issued ruling in favor of Orexigen in litigation against Actavis Laboratories FL inc for three patents for Contrave​.